Laboratoire Biomnis

Verdun, France

Laboratoire Biomnis

Verdun, France
SEARCH FILTERS
Time filter
Source Type

Thibault V.,Laboratoire Of Virologie | Thibault V.,University of Rennes 1 | Servant-Delmas A.,Sanguine | Ly T.D.,Laboratoire Biomnis | And 2 more authors.
Journal of Clinical Virology | Year: 2017

Background The impact of hepatitis B virus (HBV) genomic variability on the measurement of HBsAg level has been poorly evaluated. Objective This study was designed to compare the performance of all the available assays measuring HBsAg level in this setting. Study design A large selection of wild type HBV genotypes (n = 184) and HBsAg strains harboring mutations in the S gene (n = 81) from clinical samples was studied with three HBsAg quantification assays: Architect HBsAg (Abbott), LiaisonXL Murex HBsAg Quant (DiaSorin) and the Elecsys HBsAgII (Roche). Results The overall percentage of positive results was 99.2% for Abbott, 98.9% for DiaSorin and 98.1% for Roche. Abbott and Roche assays provided an excellent concordance in HBsAg quantification (global mean bias of −0.006 logIU/mL). By contrast, DiaSorin underestimated HBsAg level with values 0.112 logIU/ml and 0.103 logIU/ml lower than Abbott and Roche, respectively. By contrast, DiaSorin slightly over quantified gtC (2.5% over the expected value) while Abbott provided values 6.2% lower than expected and 16.2% lower than what observed for the other genotypes. HBsAg quantitative assays were influenced by HBs protein substitutions irrespective to the genotype but no specific protein pattern that would particularly impair the quantification by one technique has been identified. However, Roche seemed to be particularly impacted by substitutions at 145 residue: 75% of under quantified samples carried a substituted 145 residue. Conclusion This head-to-head comparison indicates a good correlation between all current systems used to quantify HBsAg but clearly shows an influence of both the genotype and the presence of “a” determinant variants in the absolute quantification of HBsAg. While these discrepancies may not translate into major clinical consequence, they may explain an absence of detection of weak concentration of HBsAg on some systems. © 2017 Elsevier B.V.


PubMed | Service de gynecologie, Service de gastro enterologie, Service de pediatrie generale, Nancy University Hospital Center and 37 more.
Type: Journal Article | Journal: Geriatrie et psychologie neuropsychiatrie du vieillissement | Year: 2016

The number of serum 25-hydroxyvitamin D (25OHD) assays has increased tenfold in France in less than 10 years, sometimes for invalidated reasons. In 2013, the French National Authority for Health (Haute autorit de sant, or HAS) limited the indications for serum 25OHD measurements to rickets/osteomalacia, older adults with recurrent falls, monitoring of kidney transplant in adults, and surgical treatment of obesity in adults. Our aim here was to note that other indications for serum 25OHD measurements are supported by previous literature and by a number of national and international recommendations, in particular the following: any situation of bone fragility, any chronic renal failure <45 mL/min/1.73m


Rabut E.,Laboratoire Biomnis | Castro-Fernandez A.,Laboratoire Biomnis | Gall V.L.,Laboratoire Biomnis | Meknache N.,Laboratoire Biomnis
Annales de Biologie Clinique | Year: 2017

We report the case of a 54 years old patient monitored for a monoclonal IgG kappa light chain refractory relapsed multiple myeloma and receiving daratumumab immunotherapy. Daratumumab (DARA), a monoclonal anti- CD38 antibody, belongs to the new generation of immunotherapy in refractory relapse multiple myeloma which the medical pathologist should be aware of to avoid misinterpretation of biological tests performed for patients followed for this disease. By its IgG1K humanized monoclonal antibody backbone, DARA interferes in both serum protein electrophoresis and immunofixation by the presence of an alternate IgGK monoclonal peak, leading to a possible difficulty to assess treatment's response in monoclonal IgG kappa light chain myeloma. By its intrinsic anti-CD38 activity DARA also interferes in the screening and identification of red blood cells alloantibodies, due to stabilized red cells reagent expressing weakly the CD38 molecule. We manage to overcome this last interference by using dithiotreitol. © Copyright 2017 John Libbey Eurotext.


Samama M.M.,Groupe hospitalier Broca Cochin | Samama M.M.,Laboratoire Biomnis | Gerotziafas G.,Hopital Tenon
Bio Tribune Magazine | Year: 2011

Vitamin K antagonists (VKA) and heparins are the commonly used therapeutics in the prevention of venous and arterial thromboembolic episodes. They have numerous advantages and few flaws: iatrogenicity and compulsory biological monitoring for the VKA, and activity limited to the parenteral way for heparins. Three new oral anticoagulants, direct inhibitors of factor Xa (Rivaroxaban, Apixaban) or of factor IIa or thrombin (Dabigatran Etexilate), do not need coagulation monitoring. The diet does not influence the activity of these 3 new molecules. A small number of drugs can modify their anticoagulant activity. The thromboprophylaxis in major orthopedic surgery and the non valvular atrial fibrillation are registered by the Health Authorities. Their use in the treatment of venous thromboembolic episodes and the prevention of recurrence or secondary prevention has not been yet validated by the Health Authorities. The physician's information and the patient's education are strongly recommended for the success of this therapeutic revolution. © 2011 Springer Verlag France.


Servant-Delmas A.,Sanguine | Mercier-Darty M.,Sanguine | Ly T.D.,Laboratoire Biomnis | Wind F.,Etablissement Francais du Sang | And 3 more authors.
Journal of Clinical Virology | Year: 2012

Background: Natural variation and mutations in the envelope protein (S) of hepatitis B virus can translate into HBsAg variants no longer detectable by conventional HBsAg assays. Objectives: The aim of the study was to assess the performance of 13 commercial assays currently used for screening and clinical analysis of HBsAg variants. Study design: The limit of detection (LOD) for each assay was established using two reference standards (WHO HBsAg 00/588 and the SFTS French reference). Sensitivity was evaluated using different panels. Panel 1 included 25 recombinant HBs variants at three concentrations, panels 2 and 4 included 8 recombinant HBsAg variants and 9 wild-type proteins (genotypes A-F), respectively, panel 3 included 16 natural HBsAg variants. Results: LODs ranged from 0.011 to 0.095. IU/ml with the WHO standard, and from 0.021 to 0.326. ng/ml with the French reference. The overall percentage of positive signals using HBsAg variants ranged from 62.9% to 97.9%. Three substitutions: T123, D144A and G145, were negative at all concentrations with at least one assay. Discussion: Our findings show that, although they fulfil CE requirements for analytical sensitivity (LODs below 0.13. IU/ml), HBsAg assays may vary in their capacity to detect HBsAg variants. This limit in diagnosis performance should encourage the health regulatory agencies to include HBsAg variant panels in the evaluation process. © 2012 Elsevier B.V.


PubMed | Center National Of Reference Des Mycobacteries Et Of La Resistance Aux Antituberculeux, Laboratoire Biomnis, Montpellier University and CHRU Montpellier
Type: | Journal: Annals of clinical microbiology and antimicrobials | Year: 2016

The agar dilution method is currently considered as the reference method for Mycobacterium marinum drug susceptibility testing (DST). As it is time-consuming, alternative methods, such as the E-test, were evaluated for M. marinum DST, but without success. The SLOMYCO Sensititre() panel, recently commercialized by TREK Diagnostic Systems (Cleveland, OH), can be used for DST in slow-growing mycobacteria and for antimicrobial agents recommended by the Clinical and Laboratory Standards Institute (CLSI) for M. marinum DST. The main goal of this work was to evaluate the SLOMYCO Sensititre() panel method for DST in M. marinum isolates from human patients and fish relative to the reference agar dilution method.The reproducibility of the minimum inhibitory concentration (MIC) determination (1 log2 dilution) was very good for both the agar dilution method and SLOMYCO Sensititre() panel (>90% agreement). The percentage essential agreement between methods varied, depending on the drug: between 97 and 75% for ciprofloxacin, moxifloxacin, linezolid, isoniazid, clarithromycin, amikacin, rifabutin and rifampin, 74% for trimethoprim, 72% for doxycycline, 70% for sulfamethoxazole, 59% for streptomycin, 33% for ethambutol and only 2.2% for ethionamide. When the agar dilution and SLOMYCO Sensititre() panel results were converted into interpretive criteria, the category agreement was 100% for amikacin, ciprofloxacin, clarithromycin, moxifloxacin, rifabutin, sulfamethoxazole and trimethoprim, 98% for ethambutol and 96% for rifampin and no agreement for doxycycline.The SLOMYCO Sensititre() panel method could provide a potential alternative to the reference agar dilution method, when DST in M. marinum is required, except for doxycycline.


Gonzalo P.,University of Lyon | Pecquet M.,University of Lyon | Bon C.,University of Lyon | Gonzalo S.,Laboratoire Biomnis | And 3 more authors.
Clinica Chimica Acta | Year: 2012

Background: The CDT assay used to detect chronic alcohol abuse is difficult with cirrhotic patients. This article describes the performances of several CDT assays in case of cirrhosis. The CDT-Capillarys assay by capillary zone electrophoresis was used for initial testing. Two additional methods were tested as putative confirmatory methods. Methods: 110 patients with known hepatic status had their CDT measured by the Capillarys2 or alternative methods. Self-reported alcohol intake was used to assess the performances of CDT assays. Results: Capillarys2 performance was lower in case of cirrhosis, many electropherograms displaying various abnormalities. We used the proper separation of the di- and tri-sialotransferrin peaks to select reliable profiles. This selection led to the classification of cirrhotic and non-cirrhotic patients in abusers and abstainers with similar performances. However, no interpretation was available for 54% of the cirrhotic patients and neither the BioRad %CDT by HPLC test, nor the Siemens N-Latex CDT kit was suitable as confirmatory methods for these samples. Conclusions: An attentive profile examination is required for the validation of Capillarys CDT results of cirrhotic patients. Reliability is significantly improved when samples with an improper separation are excluded. To date, no commercial test can confirm the excluded samples. © 2012 Elsevier B.V.

Loading Laboratoire Biomnis collaborators
Loading Laboratoire Biomnis collaborators